Taken together, our findings indicate that the linc‐UFC1 expression signature may serve as a novel biomarker for the diagnosis and prognosis of cervical cancer, and it is also highlighted that the E2F1‐linc‐UFC1/miR‐34a/FOXP3 axis may be a potentially therapeutic target of cervical cancer. This evidence concerns the gene FOXP3 and cervical carcinoma.